Skip to content

In the BioHarmony Drug Report Database

Dextroamphetamine saccharate

Adderall, Mydayis (dextroamphetamine saccharate) is a small molecule pharmaceutical. Dextroamphetamine saccharate was first approved as Adderall on 1996-02-13. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA. It is known to target trace amine-associated receptor 1, sodium-dependent dopamine transporter, and sodium-dependent noradrenaline transporter. Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate's patents are valid until 2029-08-24 (FDA).
Trade Name Adderall, Mydayis
Common Name Dextroamphetamine saccharate
Indication attention deficit disorder with hyperactivity, narcolepsy
Drug Class
Dextroamphetamine saccharate
Get full access now